Alnylam Pharmaceuticals, Inc. vs Pfizer, Inc. — Stock Comparison
Q·Score Breakdown
8
Bullish
Overall
6.5
Neutral
Quality
Health
Growth
Valuation
Sentiment
ALNY
Consensus analyst target of $449.48 is 52% above current price.
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
BUY
Target $449.48 (+51.8%)
25 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts
Fundamentals
ALNY
PFE
74.6×
Trailing P/E
19.4×
21.2×
Forward P/E
9.4×
12.6%
Profit Margin
12.4%
80.8%
Gross Margin
75.8%
90.4%
ROE
8.9%
96.4%
Revenue Growth
-1.2%
—
Earnings Growth
—
0.38
Beta
0.39
—
Price / Book
—
$39.5B
Market Cap
$149.8B
$246 – $496
52-Week Range
$22 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →